{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T02:21:42Z","timestamp":1779243702072,"version":"3.51.4"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,7,28]],"date-time":"2017-07-28T00:00:00Z","timestamp":1501200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2017,7,28]],"date-time":"2017-07-28T00:00:00Z","timestamp":1501200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1007\/s40744-017-0069-z","type":"journal-article","created":{"date-parts":[[2017,7,28]],"date-time":"2017-07-28T05:20:54Z","timestamp":1501219254000},"page":"503-508","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Brazilian Experience of the Treatment of Alopecia Universalis with the Novel Antirheumatic Therapy Tofacitinib: A Case Series"],"prefix":"10.1007","volume":"4","author":[{"given":"Morton","family":"Scheinberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Regina Adalva","family":"de Lucena Couto Oc\u00e9a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boris Afonso","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sineida Berbert","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,7,28]]},"reference":[{"key":"69_CR1","doi-asserted-by":"publisher","first-page":"S513","DOI":"10.1038\/jidsymp.2013.4","volume":"16","author":"MK Hordinsky","year":"2013","unstructured":"Hordinsky MK. Overview of alopecia areata. J Investig Dermatol Symp Proc. 2013;16:S513\u20135.","journal-title":"J Investig Dermatol Symp Proc"},{"issue":"8","key":"69_CR2","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1172\/JCI31942","volume":"117","author":"Amos Gilhar","year":"2007","unstructured":"Gilhar A, Paus R, Kalish RS. Lymphocytes, neuropeptides, and genes involved in alopecia areata. J Clin Invest. 2007;117:2019\u201327.","journal-title":"Journal of Clinical Investigation"},{"key":"69_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jdermsci.2016.10.004","volume":"86","author":"T Dainichi","year":"2017","unstructured":"Dainichi T, Kabashima K. Alopecia areata: what\u2019s new in epidemiology, pathogenesis, diagnosis, and therapeutic options? J Dermatol Sci. 2017;86:3\u201312 (Review).","journal-title":"J Dermatol Sci"},{"issue":"1","key":"69_CR4","first-page":"e89776","volume":"22","author":"MK Crispin","year":"2016","unstructured":"Crispin MK, Ko JM, Craiglow BG, Cerise JE, et al. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata. JCI Insight. 2016;22(1):e89776.","journal-title":"JCI Insight."},{"issue":"165","key":"69_CR5","doi-asserted-by":"publisher","first-page":"750","DOI":"10.7326\/L16-0125","volume":"15","author":"M Scheinberg","year":"2016","unstructured":"Scheinberg M, Ferreira SB. Reversal of alopecia universalis by tofacitinib: a case report. Ann Intern Med. 2016;15(165):750\u20131.","journal-title":"Ann Intern Med"},{"key":"69_CR6","first-page":"1","volume":"22","author":"A Samadi","year":"2017","unstructured":"Samadi A, Ahmad Nasrollahi S, Hashemi A, Nassiri Kashani M, Firooz A. Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature. J Dermatol Treat. 2017;22:1\u201311.","journal-title":"J Dermatol Treat."},{"issue":"1","key":"69_CR7","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s10067-016-3436-1","volume":"36","author":"R Fleischmann","year":"2016","unstructured":"Fleischmann R, Mease PJ, Schwartzman S, et al. Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group. Clin Rheumatol. 2017;36(1):15\u201324.","journal-title":"Clinical Rheumatology"},{"key":"69_CR8","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1097\/MOP.0000000000000375","volume":"28","author":"JF Rork","year":"2016","unstructured":"Rork JF, Rashighi M, Harris JE. Understanding autoimmunity of vitiligo and alopecia areata. Curr Opin Pediatr. 2016;28:463\u20139.","journal-title":"Curr Opin Pediatr"},{"key":"69_CR9","doi-asserted-by":"publisher","first-page":"2988","DOI":"10.1038\/jid.2014.260","volume":"134","author":"BG Craiglow","year":"2014","unstructured":"Craiglow BG, King BA. Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis. J Invest Dermatol. 2014;134:2988\u201390.","journal-title":"J Invest Dermatol."},{"key":"69_CR10","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jaad.2016.09.007","volume":"76","author":"LY Liu","year":"2017","unstructured":"Liu LY, Craiglow BG, Dai F, King BA. Tofacitinib for the treatment of severe alopecia areata and variants: a study of 90 patients. J Am Acad Dermatol. 2017;76:22\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"69_CR11","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1159\/000445182","volume":"22","author":"F Anzengruber","year":"2016","unstructured":"Anzengruber F, Maul JT, Kamarachev J, Tr\u00fceb RM, French LE, Navarini AA. Transient efficacy of tofacitinib in alopecia areata universalis. Case Rep Dermatol. 2016;22(8):102\u20136.","journal-title":"Case Rep Dermatol."},{"key":"69_CR12","doi-asserted-by":"crossref","unstructured":"Kassira S, Korta DZ, Chapman L, Dann F. Review of treatment for alopecia totalis and alopecia universalis. Int J Dermatol. 2017. (epub ahead of print).","DOI":"10.1111\/ijd.13612"},{"key":"69_CR13","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1093\/rheumatology\/keu145","volume":"53","author":"J Bene","year":"2014","unstructured":"Bene J, Moulis G, Aufrett M, et al. Alopecia induced by tumor necrosis factor: description of 52 cases and disproportionally analysis in a nationwide pharmacovigilance database. Rheumatology. 2014;53:1465\u20139.","journal-title":"Rheumatology"},{"issue":"4","key":"69_CR14","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/ncprheum0738","volume":"4","author":"Ieda MM Laurindo","year":"2008","unstructured":"Laurindo IM, Scheinberg M. Why do some biological agents induce psoriasis or psoriasiform lesions? Nat Clin Pract Rheumatol. 2008;4:168\u20139.","journal-title":"Nature Clinical Practice Rheumatology"},{"key":"69_CR15","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","volume":"77","author":"S Banerjee","year":"2017","unstructured":"Banerjee S, Biehl A, Gadina M, Hasni S, Schwartz DM. JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects. Drugs. 2017;77:521\u201346.","journal-title":"Drugs"},{"key":"69_CR16","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1007\/s10067-017-3574-0","volume":"36","author":"JA Jaller","year":"2017","unstructured":"Jaller JA, Jaller JJ, Jaller AM, et al. Recovery of nail dystrophy potential new therapeutic indication of tofacitinib. Clin Rheumatol. 2017;36:971\u20133.","journal-title":"Clin Rheumatol"},{"key":"69_CR17","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrrheum.2017.23","volume":"13","author":"KL Winthrop","year":"2017","unstructured":"Winthrop KL. The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol. 2017;13:234\u201343.","journal-title":"Nat Rev Rheumatol"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-017-0069-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-017-0069-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-017-0069-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T00:05:17Z","timestamp":1724457917000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-017-0069-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,28]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["69"],"URL":"https:\/\/doi.org\/10.1007\/s40744-017-0069-z","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,28]]},"assertion":[{"value":"1 June 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2017","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}